Firstpost
  • Home
  • Video Shows
    Vantage Firstpost America Firstpost Africa First Sports
  • World
    US News
  • Explainers
  • News
    India Opinion Cricket Tech Entertainment Sports Health Photostories
  • Asia Cup 2025
Apple Incorporated Modi ji Justin Trudeau Trending

Sections

  • Home
  • Live TV
  • Videos
  • Shows
  • World
  • India
  • Explainers
  • Opinion
  • Sports
  • Cricket
  • Health
  • Tech/Auto
  • Entertainment
  • Web Stories
  • Business
  • Impact Shorts

Shows

  • Vantage
  • Firstpost America
  • Firstpost Africa
  • First Sports
  • Fast and Factual
  • Between The Lines
  • Flashback
  • Live TV

Events

  • Raisina Dialogue
  • Independence Day
  • Champions Trophy
  • Delhi Elections 2025
  • Budget 2025
  • US Elections 2024
  • Firstpost Defence Summit
Trending:
  • Nepal protests
  • Nepal Protests Live
  • Vice-presidential elections
  • iPhone 17
  • IND vs PAK cricket
  • Israel-Hamas war
fp-logo
CRISPR gene editing used to treat patient with beta thalassemia blood disorder
Whatsapp Facebook Twitter
Whatsapp Facebook Twitter
Apple Incorporated Modi ji Justin Trudeau Trending

Sections

  • Home
  • Live TV
  • Videos
  • Shows
  • World
  • India
  • Explainers
  • Opinion
  • Sports
  • Cricket
  • Health
  • Tech/Auto
  • Entertainment
  • Web Stories
  • Business
  • Impact Shorts

Shows

  • Vantage
  • Firstpost America
  • Firstpost Africa
  • First Sports
  • Fast and Factual
  • Between The Lines
  • Flashback
  • Live TV

Events

  • Raisina Dialogue
  • Independence Day
  • Champions Trophy
  • Delhi Elections 2025
  • Budget 2025
  • US Elections 2024
  • Firstpost Defence Summit
  • Home
  • Tech
  • science
  • CRISPR gene editing used to treat patient with beta thalassemia blood disorder

CRISPR gene editing used to treat patient with beta thalassemia blood disorder

tech2 News Staff • March 1, 2019, 20:20:22 IST
Whatsapp Facebook Twitter

There’s technically a chance that the patient may be fully-cured of thalassemia after the treatment.

Advertisement
Subscribe Join Us
Add as a preferred source on Google
Prefer
Firstpost
On
Google
CRISPR gene editing used to treat patient with beta thalassemia blood disorder

A health care startup in Switzerland has just used gene editing technology CRISPR to treat a person with a genetic blood disorder called beta thalassemia. This is certainly a first for the company, CRISPR Therapeutics, but also for the entire Western healthcare industry. It is the first time gene editing has been used as treatment by any clinic in the West. The study also has a medical partner, Vertex Pharmaceuticals, that is sponsoring the transfusions needed for the patient(s). Doctors in China, however, have already beaten the rest of the world to the chase, having used **gene editing** to treat patients with cancer, the MIT Technology Review reported. **Beta thalassemia** is a deadly blood disease that leaves most of its patients very dependent on regular transfusions. The disease is genetic, caused when somebody inherits a faulty or mutated copy of the haemoglobin gene. Haemoglobin is a critically important vessel in the blood for oxygen transport. [caption id=“attachment_6179371” align=“alignnone” width=“1280”] ![Red Blood Cells lookin' fine and healthy (1)](https://images.firstpost.com/wp-content/uploads/2019/03/Red-Blood-Cells-lookin-fine-and-healthy-1.jpg) Red Blood Cells lookin’ fine & healthy. Image courtesy: MIT[/caption] “Treating the first patient in this study marks an important scientific and medical milestone,” Samarth Kulkarni, CEO of CRISPR Therapeutics, said in a press release, “and the beginning of our efforts to fully realize the promise of **CRISPR/Cas9 therapies** as a new class of potentially transformative medicines to treat serious diseases.” In the new clinical trial, CRISPR is being used in two different ways. First, bone marrow cells were collected from patients and the DNA in them “fixed” by replacing the faulty **haemoglobin gene** with a healthy one. These DNA-altered bone marrow cells are then transfused back into the patients’ blood. This is quite a promising strategy, considering there’s a “technical” possibility that the patient is fully cured of the disease after the treatment — that’s if there are enough “healthy” bone marrow cells that multiply, make more of themselves and continue to keep their numbers decent over time. This best case scenario isn’t something the company can guarantee for now. [caption id=“attachment_6179361” align=“alignnone” width=“1280”]The treatments at hand for Beta thalassemia other than gene editing. Image courtesy: MyBioSource.org The treatments at hand for Beta thalassemia other than gene editing. Image courtesy: MyBioSource.org[/caption] The company also plans to use the same technique to treat sickle-cell anaemia, another blood disorder that is both genetic and linked with haemoglobin. The second CRISPR strategy used by the startup is switching on a different gene in the body — one that helps produce fetal haemoglobin. This version, as is obvious from the name, is a kind of haemoglobin that is useful to us when we’re infants. It turns off automatically by 6 months after birth, by when all the fetal haemoglobin is replaced by mature haemoglobin cells. CRISPR is being used here to switch the dormant fetal haemoglobin gene back on so it can compensate for the low counts of healthy haemoglobin. Blueprints for a formal trial with multiple patients have already been made, but the company wants to wait to see how their patient zero responds before treating others.

Tags
CRISPR CRISPR Cas9 SciTech CRISPR Gene Editing Vertex Pharmaceuticals
End of Article
Latest News
Find us on YouTube
Subscribe
End of Article

Top Stories

Israel targets top Hamas leaders in Doha; Qatar, Iran condemn strike as violation of sovereignty

Israel targets top Hamas leaders in Doha; Qatar, Iran condemn strike as violation of sovereignty

Nepal: Oli to continue until new PM is sworn in, nation on edge as all branches of govt torched

Nepal: Oli to continue until new PM is sworn in, nation on edge as all branches of govt torched

Who is CP Radhakrishnan, India's next vice-president?

Who is CP Radhakrishnan, India's next vice-president?

Israel informed US ahead of strikes on Hamas leaders in Doha, says White House

Israel informed US ahead of strikes on Hamas leaders in Doha, says White House

Israel targets top Hamas leaders in Doha; Qatar, Iran condemn strike as violation of sovereignty

Israel targets top Hamas leaders in Doha; Qatar, Iran condemn strike as violation of sovereignty

Nepal: Oli to continue until new PM is sworn in, nation on edge as all branches of govt torched

Nepal: Oli to continue until new PM is sworn in, nation on edge as all branches of govt torched

Who is CP Radhakrishnan, India's next vice-president?

Who is CP Radhakrishnan, India's next vice-president?

Israel informed US ahead of strikes on Hamas leaders in Doha, says White House

Israel informed US ahead of strikes on Hamas leaders in Doha, says White House

Top Shows

Vantage Firstpost America Firstpost Africa First Sports
Latest News About Firstpost
Most Searched Categories
  • Web Stories
  • World
  • India
  • Explainers
  • Opinion
  • Sports
  • Cricket
  • Tech/Auto
  • Entertainment
  • IPL 2025
NETWORK18 SITES
  • News18
  • Money Control
  • CNBC TV18
  • Forbes India
  • Advertise with us
  • Sitemap
Firstpost Logo

is on YouTube

Subscribe Now

Copyright @ 2024. Firstpost - All Rights Reserved

About Us Contact Us Privacy Policy Cookie Policy Terms Of Use
Home Video Shorts Live TV